IAN MORTIMER - 28 Nov 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
28 Nov 2025
Net transactions value
-$4,366
Form type
4
Filing time
03 Dec 2025, 20:20:44 UTC
Previous filing
01 Oct 2025
Next filing
09 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MORTIMER IAN PRESIDENT & CEO, Director 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA /s/ Nathaniel Adams, Attorney-in-fact 03 Dec 2025 0001619961

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Sale $4,366 -97 -0.31% $45.01 31,205 28 Nov 2025 Direct F1
holding XENE Common Shares 14,300 28 Nov 2025 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024.